- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03870490
Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects
May 3, 2019 updated by: Venatorx Pharmaceuticals, Inc.
An Open-Label Trial to Assess the Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects
This is a single-center, open-label study to assess safety and pharmacokinetics of VNRX-5133 and cefepime in the epithelial lining fluid in healthy adult male and female subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06102
- Hartford Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing to participate in the trial, give written informed consent, and comply with the trial restrictions
- Gender: male or female with a negative serum pregnancy test (β-human chorionic gonadotropin [β-hCG]) at Screening and Day -1; females may be of childbearing potential or of nonchildbearing potential
- Age: ≥18 years at Screening
- Weight: ≥50 kg
- Body mass index (BMI): ≥18 kg/m2 and <30 kg/m2
- Normal blood pressure (BP), defined as a systolic value ≥90 mm Hg and ≤140 mm Hg and a diastolic value <90 mm Hg (Screening and Day -1)
- All values for hematology and clinical chemistry tests of blood and urine are either within normal limits of laboratory reporting range (WNL) or defined as permitted exceptions
- Ability and willingness to abstain from alcohol, from 48 hours (2 days) prior to admission to the Clinical Research Center (CRC) until discharge from the CRC
- Males who are not surgically sterilized and females of childbearing potential must agree to use highly effective methods of contraception during this trial and for 90 days after the last dose of study drug
- All over-the-counter (OTC) medications, health supplements, and herbal remedies (eg, St. John's Wort extract) must have been stopped at least 14 days prior to admission to the CRC
- Suitable veins for cannulation/multiple venipunctures as assessed by the Investigator at Screening
Exclusion Criteria:
- Employee of the Contract Research Organization (CRO), CRC, or the Sponsor
- Female who is pregnant, lactating, or at risk of becoming pregnant during this trial or within 90 days after the last dose of study drug
- Male with a female partner who is pregnant or lactating during this trial or planning to attempt to become pregnant during this trial or within 90 days after the last dose of study drug
- Use of any investigational drug or device within 30 days prior to Screening (90 days for an injectable biological agent)
- Presence of a congenital or acquired immunodeficiency syndrome
- Any evidence or history of clinically significant medical abnormalities on PE or laboratory assessment
- Clinically significant ECG abnormality
- Sitting systolic BP >140 mm Hg or diastolic BP >90 mm Hg on a single measurement following at least 5 minutes of rest at Screening
- History of drug allergy of a severity that required urgent medical treatment such as treatment with epinephrine in an Emergency Department
- History of any hypersensitivity reaction following administration of a cephalosporin, penicillin, or other β-lactam antibacterial drug or any component of VNRX-5133 for injection formulation
- History of hypersensitivity to lidocaine, midazolam, fentanyl, or other topical anesthetics/opioids in similar classes to these agents
- Use of prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to the first dose of study drug
- History of donation of >450 mL of blood within 60 days prior to first dose of study drug or planned donation before 30 days has elapsed since final dose of study drug
- Plasma or platelet donation within 7 days of first dose of study drug or planned donation during this trial
- Current suspected drug or alcohol abuse as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision criteria
- Recent history of alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 standard drink=5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months before Screening
- Use of tobacco- or nicotine-containing products from Screening through Check Out
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Subjects
VNRX-5133 + cefepime
|
IV infusion (3 doses)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)
Time Frame: Day 2
|
Steady-state plasma PK and disposition of cefepime/VNRX-5133 in the ELF
|
Day 2
|
Safety as measured by the number of subjects with adverse events
Time Frame: Days 1-7
|
Number of Subjects with AEs (Assessed via patient report, physical exam, ECGs, vital signs, laboratory investigations, and use of concomitant medications for the treatment of AEs)
|
Days 1-7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2019
Primary Completion (Actual)
April 1, 2019
Study Completion (Actual)
April 1, 2019
Study Registration Dates
First Submitted
March 8, 2019
First Submitted That Met QC Criteria
March 8, 2019
First Posted (Actual)
March 12, 2019
Study Record Updates
Last Update Posted (Actual)
May 6, 2019
Last Update Submitted That Met QC Criteria
May 3, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VNRX-5133-106
- 272201300019C-17-0-3 (U.S. NIH Grant/Contract)
- 18-0001 (Other Identifier: DMID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Vigonvita Life SciencesNot yet recruiting
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
Clinical Trials on VNRX-5133 + cefepime
-
Venatorx Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Venatorx Pharmaceuticals, Inc.CompletedUrinary Tract Infections | Acute PyelonephritisUnited States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Latvia, Mexico, Peru, Romania, Russian Federation, Serbia, Turkey, Ukraine
-
Venatorx Pharmaceuticals, Inc.National Institutes of Health (NIH)CompletedPharmacokineticsUnited States
-
Venatorx Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Venatorx Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Venatorx Pharmaceuticals, Inc.Novotech (Australia) Pty LimitedTerminated
-
Venatorx Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
Venatorx Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Breast Cancer | Primary Myelofibrosis | Multiple Myeloma | Ovarian Epithelial Cancer | Chronic Myelomonocytic Leukemia | Neutropenia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone... and other conditionsUnited States